Fingolimod impairs inactivated vaccine (CoronaVac)-induced antibody response to SARS-CoV-2 spike protein in persons with multiple sclerosis.

Creative Commons License

Türkoğlu R., Baliç N., Kızılay T., Erol R., Akbayır E., Yılmaz V., ...More

Multiple sclerosis and related disorders, vol.58, pp.103524, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Letter
  • Volume: 58
  • Publication Date: 2022
  • Doi Number: 10.1016/j.msard.2022.103524
  • Journal Name: Multiple sclerosis and related disorders
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Page Numbers: pp.103524
  • Keywords: COVID-19, SARS-COV-2, Vaccination, CoronaVac, Multiple sclerosis, Fingolimod
  • Istanbul University Affiliated: Yes


Background: : The impact of disease-modifying treatments on humoral response induced by inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines is understudied. Methods: : We recruited 34 persons with multiple sclerosis (MS) under fingolimod treatment and 25 healthy individuals. Anti-SARS-CoV-2 spike IgG indices were measured by ELISA in sera of participants after CoronaVac vaccinations. Results: : Persons with MS displayed significantly lower antibody levels and seropositivity prevalence. Persons with MS with longer fingolimod treatment durations displayed lower anti-SARS-CoV-2 indices. Conclusion: : Our results support previous findings regarding humoral response impairing effect of fingolimod after vaccinations. Patients under fingolimod treatment may require closer monitoring for COVID-19.